



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

16th November, 2022

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir / Madam,

Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/15/2022-23

LEGAL UPDATE

Hyderabad, 16th November, 2022

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to update that the Appeals Court in the US has rejected its marketing partner Alvogen's appeal on Ibrutinib Tablets of 140 mg, 280 mg, 420 mg and 560 mg strength (proposed generic equivalents to Imbruvica® Tablets).

Natco and its co-development & marketing partner, Alvogen Pine Brook LLC, USA, are assessing their option on the way forward.

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer